Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model-Reference-Cited by-同舟云学术

Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model

Published:2021-04-19 Issue:5 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Portillo-Calderón I.¹²^ORCID,Ortiz-Padilla M.¹²^ORCID,de Gregorio-Iaria B.¹,Merino-Bohorquez V.³,Blázquez J.⁴^ORCID,Rodríguez-Baño J.¹²⁵^ORCID,Rodríguez-Martínez J. M.²⁶^ORCID,Pascual A.¹²⁶^ORCID,Docobo-Pérez F.²⁶⁷^ORCID

Affiliation:

1. Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, Seville, Spain

2. Instituto de Biomedicina de Sevilla IBIS, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, Spain

3. Unidad de Gestión de Farmacia Hospitalaria, Hospital Universitario Virgen Macarena, Seville, Spain

4. Centro Nacional de Biotecnología, Madrid, Spain

5. Departamento de Medicina, Universidad de Sevilla, Seville, Spain

6. Departamento de Microbiología, Universidad de Sevilla, Seville, Spain

7. F. Docobo-Pérez, Departamento de Microbiología, Universidad de Sevilla, Seville, Spain

Abstract

We evaluated human-like the efficacy of intravenous doses of fosfomycin of 8 g every 8 h (8 g/Q8h) and of amikacin (15 mg/kg/Q24h) in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a hollow-fiber infection model (HFIM). Six fosfomycin-heteroresistant E. coli isolates (four with strong mutator phenotype) and the control strain E. coli ATCC 25922 were used.

Funder

MEC | Instituto de Salud Carlos III

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02213-20

Reference43 articles.

1. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

2. O’Neill J. 2016. Review on antibiotic resistance. antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance London United Kingdom. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.

3. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018

4. Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant

5. Clinical Laboratory Standard Institute. 2020. Performance standards for antimicrobial susceptibility testing, 30th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature;Journal of Antimicrobial Chemotherapy;2024-08-31

2. Applications of the hollow-fibre infection model (HFIM) in viral infection studies;Journal of Antimicrobial Chemotherapy;2022-11-22

3. Effect of Glycerol on Fosfomycin Activity against Escherichia coli;Antibiotics;2022-11-12

4. Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin–Resistant Enterococcus faecium in a Hollow Fiber Infection Model;Frontiers in Microbiology;2021-12-14